Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




POCT Market Reaches USD 18 Billion in 2016

By LabMedica International staff writers
Posted on 10 Mar 2017
Sales of point of care (POC) diagnostic testing, both professional testing and self-testing, reached USD 18.4 billion in 2016, driven by emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices that aim to provide expedited diagnosis where the patient is seen or in the patient’s home. More...
These new technologies are allowing POC devices to generate quantitative lab-quality test results and transfer them automatically to an information system, a remote caregiver service for consultation or an electronic medical record.

These are the latest findings of Kalorama Information, an independent medical market research firm.

Over the past 10 years, POC test devices have contributed significantly to the growth of the overall diagnostics market. A large number of diagnostic manufacturers have focused on obtaining CLIA waiver status for their POC devices and CE Mark for POC or self-use. Additionally, more decentralized test venues are investing in non-waived rapid tests and instruments POC testing is expected to play an even more significant role in diagnosis and monitoring patient care.

Currently, molecular POC tests in physician office are available for respiratory infections and more. The market for POC molecular test devices will be driven by their ability to provide precise answers for time sensitive tests, such as sexually transmissible diseases and other infections.

However, with lab budgets across the world being cut for test send-outs, there is a lack of trained technologists to run molecular tests in their present configuration. The new pharma model will resolve this by tailoring therapy to the individual’s particular disease physiology, often determined by the results of a diagnostic test. As a result, more tests – molecular and immunoassays – are expected to come to market, with their adoption being based on performance data, contribution to patient outcome and cost/benefit analysis.

An aging population across the world will provide sufficient room for growth of the POC testing market in the developing as well as developed countries. The evolving POC testing market comprises large and small companies involved in development and/or marketing. The key companies are likely to maintain their leading position in the market through continued product innovation and strategic alliances and mergers.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.